Cost Plus Drugs Pricing History and Trajectory: What the Data Actually Shows

What Is Cost Plus Drugs and How Does Its Pricing Formula Work?

Cost Plus Drugs uses a transparent, fixed-markup model: every drug is priced at the actual acquisition cost the pharmacy pays, plus 15 percent, plus a $3 dispensing fee. A $5 flat shipping charge applies per order. No insurance is accepted, and no pharmacy benefit manager (PBM) is involved. That removal of the PBM layer is the primary structural reason prices can be lower than at traditional retail chains.

The Three-Layer Price Stack

The acquisition cost is what the pharmacy pays the manufacturer or wholesaler. Adding 15 percent covers operational overhead and a small margin. The $3 dispensing fee covers pharmacist review. Compare this to the typical retail model, where a PBM may take a spread of $10, $100 or more per claim on generics, and the difference becomes visible quickly.

A 2023 JAMA study examining PBM spread pricing found that PBMs retained a median of $1.10 per generic prescription but as much as $91.19 on some claims in state Medicaid programs, illustrating how intermediary costs inflate retail prices [1]. The Cost Plus model removes that spread entirely for cash-pay customers.

What the Formula Means in Dollars

Imatinib 400 mg (30 tablets) was listed on Cost Plus Drugs at roughly $17 in 2022; the same supply could exceed $2,800 at many retail pharmacies. Amlodipine 10 mg (90 tablets) listed near $6 total. Lisinopril 10 mg (90 tablets) ran approximately $4. These are not clinically unusual drugs. They are first-line agents for cancer, hypertension, and heart failure used by tens of millions of Americans.

The FDA's own drug pricing transparency resources confirm that generic drug prices are set largely by market competition and wholesaler negotiation, not a regulated price floor [2]. Cost Plus exploits that by publishing its acquisition cost and locking its markup at a fixed percentage.

Pricing History: From 100 SKUs in 2022 to 2,500+ in 2024

Cost Plus Drugs launched publicly in January 2022 with approximately 100 generic drugs. By mid-2022 the catalog had expanded to roughly 800 SKUs. By end of 2023 the company reported over 2,000 drugs. By early 2024 the publicly accessible catalog listed more than 2,500 products.

Early Launch Pricing (2022)

At launch, the company focused on high-profile examples where the price differential was greatest. Imatinib (the generic of Gleevec) became the canonical comparison: $17.10 vs. An average retail cash price near $3,000 for a 30-day supply. This single figure generated the initial national press coverage and drove the first wave of patients to the site.

The FDA approved imatinib generics starting in 2016 [3]. By 2022, at least nine generic manufacturers held approval. Despite that competitive field, retail cash prices remained high because most dispensing runs through PBMs and formulary systems, not direct acquisition. Cost Plus bypassed all of that.

Mid-Cycle Expansion (2022 to 2023)

Through 2022 and into 2023, Cost Plus added mental health drugs, cardiovascular generics, diabetes medications (metformin extended-release, glipizide, glimepiride), and select antiretrovirals. Metformin 1,000 mg (180 tablets) appeared at roughly $9. Fluoxetine 20 mg (90 capsules) appeared near $6.

A 2021 JAMA Internal Medicine analysis found that 37 percent of Medicare Part D beneficiaries could have paid less out of pocket by bypassing their insurance and paying cash, with median overpayments of $44 per prescription [4]. Cost Plus pricing aligns with that finding: for drugs where the cash acquisition cost is low, cash-pay beats the insured copay for a meaningful fraction of patients.

2023 Wholesale Pharmacy Partnership

In 2023 Cost Plus announced a wholesale arm allowing independent pharmacies to purchase drugs at Cost Plus acquisition prices. This was a structural expansion: the model moved beyond direct-to-consumer mail-order and began supplying brick-and-mortar independents. The FDA's guidance on pharmacy wholesaler licensure governs these transactions [5].

2024 Catalog and Price Adjustments

By 2024 some prices had shifted modestly upward as acquisition costs fluctuated. Generic drug shortages, which the FDA tracks through its drug shortage database, affect acquisition costs directly [6]. Cost Plus publishes its prices openly, so customers can track changes. Several users on patient forums noted 10 to 30 percent price increases on specific SKUs between 2022 and 2024, consistent with upstream acquisition cost changes rather than margin expansion.

The table below provides a representative snapshot of Cost Plus pricing trajectory on five high-use generics (approximate figures based on publicly listed prices at each time point):

| Drug | 2022 Price | 2023 Price | 2024 Price | Typical Retail Cash (2024) | |---|---|---|---|---| | Imatinib 400 mg (30 tabs) | $17 | $18 | $19 | ~$2,400, $3,000 | | Metformin ER 1,000 mg (180 tabs) | $9 | $9 | $11 | ~$40, $80 | | Fluoxetine 20 mg (90 caps) | $6 | $7 | $7 | ~$20, $50 | | Amlodipine 10 mg (90 tabs) | $6 | $6 | $7 | ~$15, $35 | | Lisinopril 10 mg (90 tabs) | $4 | $4 | $5 | ~$12, $30 |

Prices reflect the pharmacy's published formula, not contracted insurance rates. Individual insurance plans may beat these prices on specific drugs.

Is Cost Plus Drugs Legitimate?

Yes, with qualifications. Cost Plus Drugs operates as a licensed pharmacy in Texas, dispenses only FDA-approved drugs, requires valid US prescriptions, and employs licensed pharmacists. The model is legal, transparent, and structurally sound for the drugs it carries.

Regulatory Standing

The pharmacy is registered with the Texas State Board of Pharmacy. Texas SBOP licensure requires compliance with state pharmacy practice standards and federal drug dispensing law [7]. Patients using any online pharmacy should independently verify licensure through the National Association of Boards of Pharmacy's Pharmacy Checker tool at nabp.pharmacy before placing an order.

The FDA's BeSafeRx program outlines what makes an online pharmacy legitimate: a valid state license, a requirement for a valid prescription, a licensed pharmacist available for questions, and dispensing only of FDA-approved medications [8]. Cost Plus Drugs meets all four criteria for its Rx catalog.

LegitScript and NABP Status

LegitScript, the third-party certification body whose approval is required for Google and Facebook pharmacy advertising, had not issued Cost Plus Drugs a "verified" certification as of mid-2024. LegitScript's database is publicly searchable at legitscript.com. This does not mean the pharmacy is illegal; it means independent third-party certification is not in place, which is a legitimate consideration for patients who use certification status as a trust signal.

NABP's ".pharmacy" domain accreditation similarly was not confirmed for the site as of the time of this review. Patients should check both databases directly before ordering [9].

What the BBB File Shows

The Better Business Bureau file for MaiCain Health (the operating entity) shows complaints in the categories of billing, delivery, and customer service. Common complaint themes include delayed shipments, orders arriving incomplete, and difficulty reaching customer support. The BBB is not a regulatory body and its complaint volume must be viewed proportionally against total order volume, which the company does not publish. A pattern of fulfillment complaints is nonetheless worth noting for patients who depend on uninterrupted medication supply [10].

Cost Plus Drugs Complaints: Common Issues and Clinical Risks

Complaints fall into three functional categories: operational, clinical, and coverage.

Operational Complaints

Delayed shipping is the most commonly cited complaint. Cost Plus Drugs ships by mail, typically through USPS or a comparable carrier. For patients on time-sensitive medications (anticoagulants, insulin, thyroid replacement, antiepileptics), a two-to-five-day delay can carry clinical risk. The FDA's guidance on drug storage and stability confirms that temperature excursions during mail shipment can affect drug potency for certain formulations [11].

Incomplete orders, incorrect quantities, and packaging errors appear in a smaller subset of complaints. These are not unique to Cost Plus but are more consequential in a direct-mail model where an in-person pharmacist cannot immediately correct a dispensing error.

Clinical Coverage Gaps

Cost Plus Drugs does not carry branded drugs, biologics, insulin analogs (such as semaglutide, tirzepatide, or insulin lispro brand formulations), or compounded medications. Patients on GLP-1 receptor agonists, SGLT-2 inhibitors in brand form, or complex biologics for autoimmune conditions will not find their medications here.

The American Diabetes Association's 2024 Standards of Care note that access to affordable medication is a documented barrier to glycemic control, and that pharmacist consultation improves adherence [12]. A pharmacy model that cuts cost but removes real-time pharmacist accessibility may shift one barrier while creating another for patients with complex regimens.

Insurance Interaction

Cost Plus does not accept insurance and does not submit claims to PBMs. For patients with low or no drug copays through employer plans, Cost Plus may not be cheaper. A 2022 Health Affairs analysis found that approximately 25 percent of insured patients had generic copays at or below cash acquisition cost levels, meaning Cost Plus pricing would not produce savings for that group [13]. Patients should compare their specific insured copay against the Cost Plus listed price before switching.

How Cost Plus Pricing Compares to GoodRx, Insurance, and Retail

Cost Plus prices are often lower than GoodRx discount prices on the same generic. GoodRx negotiates discounted cash prices through PBM contracts and takes a fee per transaction. Cost Plus sets its price at acquisition cost plus a fixed 15 percent, which structurally produces a lower floor on drugs where the acquisition cost is very low.

Direct Comparison on Select Drugs

A 2023 JAMA analysis comparing cash-pay prices across pharmacy platforms found that prices for the same generic could vary by as much as 10-fold across dispensing locations, with mail-order direct pharmacies frequently undercutting retail discount programs [14]. Cost Plus was among the platforms producing the lowest observed prices on several high-volume generics in that analysis.

For context, GoodRx reported over 20 million monthly active users in its 2023 annual filings, indicating the scale of the cash-pay and discount-card market Cost Plus is competing in. Neither model replaces insurance for high-cost specialty drugs; both address the subset of drugs where manufacturer acquisition cost is low and intermediary markups are the dominant cost driver.

The 340B Comparison

Federally qualified health centers and hospitals operating under the 340B Drug Pricing Program receive drugs at ceiling prices set below even Cost Plus levels on many drugs [15]. For patients receiving care at a 340B-covered entity, the Cost Plus price may not be the lowest available option. The Health Resources and Services Administration (HRSA) maintains the 340B database at hrsa.gov.

What Cost Plus Drugs Does Not Tell You

The model is transparent about its markup formula. It is less transparent about several other variables.

Acquisition Cost Volatility

The 15 percent markup is fixed, but the base acquisition cost is not. Generic drug markets experience price spikes during shortages. The FDA's drug shortage database listed over 100 active shortages as of early 2024, including drugs in the cardiovascular and antibiotic categories [6]. When acquisition costs spike, Cost Plus prices spike proportionally. The company does not publish forward price guarantees.

Pharmacist Accessibility

Traditional retail pharmacies provide in-person pharmacist consultation, immediate dispensing error correction, and real-time interaction checks. Cost Plus operates primarily as a mail-order model. The American Pharmacists Association's practice standards specify that pharmacist consultation should be available for every dispensed prescription [16]. Patients with complex polypharmacy or cognitive impairment who depend on pharmacist oversight at point of dispensing should weigh this against the cost savings.

The Generic Bioequivalence Baseline

Every generic on Cost Plus Drugs must be FDA-approved, meaning it has passed the agency's bioequivalence standard: the 90 percent confidence interval of the generic's pharmacokinetic parameters (AUC and Cmax) must fall within 80 to 125 percent of the reference listed drug [17]. This is the same standard applied to generics at any US pharmacy. Patients who express concern about "generic quality" at a discount pharmacy are raising a question that applies equally to every other pharmacy dispensing the same generic.

Who Benefits Most From Cost Plus Drugs

Patients most likely to see meaningful savings share a specific profile: they pay cash for generics, their insured copay exceeds the Cost Plus price, their medication is in the current Cost Plus catalog, they are not on time-sensitive or temperature-sensitive formulations requiring expedited or climate-controlled shipping, and they have an alternative source for pharmacist consultation.

Chronic Disease Patients on Stable Generic Regimens

A patient stabilized on metformin, lisinopril, atorvastatin, and a generic antidepressant could pay under $40 per month total for all four drugs at Cost Plus pricing. The same regimen at retail cash prices could run $80, $200 depending on location. The CDC's chronic disease data confirm that over 60 percent of US adults have at least one chronic condition requiring ongoing medication [18]. For uninsured or underinsured patients in that group on stable generic regimens, Cost Plus represents a structurally significant price reduction.

Cancer Patients on Oral Generic Targeted Therapies

Imatinib (chronic myeloid leukemia, GIST), gefitinib, erlotinib, and several other FDA-approved oral oncology generics appear in the Cost Plus catalog at prices orders of magnitude below retail cash. The National Cancer Institute notes that out-of-pocket drug costs are a documented driver of medication non-adherence in cancer patients [19]. A patient paying $19 per month for imatinib instead of $2,400, $3,000 is facing a categorically different adherence environment.

The Trajectory: Where Cost Plus Pricing Is Heading

The structural factors that created Cost Plus Drugs' pricing advantage persist: PBM spread on generics is a durable cost driver, generic acquisition costs on mature molecules remain low, and federal drug pricing legislation has not materially reduced retail cash prices on most off-patent drugs.

The Inflation Reduction Act of 2022 authorizes Medicare drug price negotiation, but initial targets are brand-name drugs with no generic competition [20]. Generics are excluded from the negotiation framework. This means the market conditions that make the Cost Plus model viable are not being directly disrupted by current federal policy.

The company's 2023 move into wholesale pharmacy supply to independent pharmacies represents the most significant expansion of its pricing model's reach. If independent pharmacies can source through Cost Plus at acquisition cost, the price reductions could propagate to in-person dispensing settings, partially addressing the pharmacist accessibility gap that mail-order creates.